Aronora is engaged in the commercial development of proprietary therapeutics. Rational design of our innovative therapeutic agents is expected to result in products that may be able to reduce the growth of life-threatening blood clots without the detrimental bleeding side effects that characterize currently marketed antithrombotic drugs. Our products are intended to be used in difficult-to-treat, severe, rapidly progressing, or catastrophic thrombotic blood clotting diseases, including suspected or verified stroke, heart attack, pulmonary embolism, severe infections, and others. Building on the company’s ground-breaking approaches to superior drug safety, Aronora’s product candidates have the potential to become first-in-class medical emergency therapeutics to treat acute thrombotic diseases.
Aronora is committed to building a portfolio of safe antithrombotic drugs for a variety of clinical indications. To reach our objective, we have implemented a well-defined strategy that guides the identification of potential partnerships to support our product pipeline. We seek private investment, strategic partnerships, and out-licensing opportunities that are consistent with our business strategy. Aronora’s product development programs have been awarded several grants from the National Institutes of Health.
Aronora’s innovative approach to cardiovascular drug discovery and development provide a unique opportunity for creative individuals to make a significant impact on human health. We are committed to expanding our team with qualified, talented, and passionate individuals driven to creating exceptional products and building an exceptional company. At present, we do not have open positions. Please check back for potential openings in the near future.